Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 10/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13113767 | 0.88 | MAP3K5 (0.54) | MCHR1MAP3K5CYP2C19CYP3A4 | |
| SCHEMBL13872280 | 0.87 | MCHR1 (0.36) | MCHR1TYRO3NTRK2CLK4DYRK1B | |
| SCHEMBL13113409 | 0.83 | MCHR1 (0.48) | MCHR1NPC1RAB9APKMTYRO3 | |
| SCHEMBL13113748 | 0.83 | HTR2C (0.47) | NPC1RAB9APKMMAP3K5KDM4E | |
| SCHEMBL13113768 | 0.83 | NPC1 (0.39) | NPC1RAB9APKMMAP3K5KDM4E | |
| SCHEMBL13113354 | 0.81 | MCHR1 (0.48) | MCHR1NPC1RAB9APKMTYRO3 | |
| SCHEMBL13113735 | 0.81 | NPC1 (0.49) | MCHR1NPC1RAB9APKMKDM4E | |
| SCHEMBL13113777 | 0.78 | MAP3K5 (0.48) | MCHR1NPC1RAB9APKMMAP3K5 | |
| SCHEMBL13113763 | 0.78 | NPC1 (0.42) | NPC1RAB9APKMMAP3K5KDM4E | |
| SCHEMBL13113761 | 0.77 | MAP3K5 (0.39) | MCHR1NPC1RAB9APKMMAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The United States of America, as represented by the Secretary, Department of Health and | 2010-10-21 | — | — | US | disclosed |
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The United States of America, as represented by the Secretary, Department of Health and | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | SMN1; SMN2, SYNCRIP, RNMT | MCHR1 2055/4885NPC1 1441/4885RAB9A 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.